β-Lactam antibiotics offer neuroprotection by increasing glutamate transporter expression

By Jeffrey D. Rothstein, S. Patel, M. Regan, Christine Haenggeli, Yanhua H. Huang, D. Bergles, Lin Jin, M. Hoberg, Svetlana Vidensky, D. S. Chung and 5 more. Nature, 2005

1,436 citations recorded by the source corpus.

Subfields: Cellular and Molecular Neuroscience, Molecular Biology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/4d427445ce26dd2ca714dfc03e88193b9f96fcdf

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cellular and Molecular Neuroscience

1. M. Pekny
2. M. Sofroniew
3. M. Pekna
4. Peter W. Kalivas
5. P. Maher
6. Jana Lewerenz
7. Yun Zhou
8. H. Vinters

In Molecular Biology

1. M. Pekna
2. M. Pekny
3. M. Sofroniew
4. Gerald Seifert
5. H. Vinters
6. Yun Zhou
7. Paul Shinn
8. Peter W. Kalivas

Citations in the corpus

• Astrocyte dysfunction in neurological disorders: a molecular perspective (2006, background): “Whether activation of glutamate transporters, for example, through β-lactam antibiotic”
• Excitotoxicity and stroke: identifying novel targets for neuroprotection. (2014, positive): “1998), while increased expression of GLT-1 protects neurons against ischemic injury (Rothstein et al., 2005).”
• Glutamate as a neurotransmitter in the healthy brain (2014, background): “Ceftriaxone, increase EAAT2 expression (Rothstein et al. 2005; Berry et al. 2013).”
• The NCGC Pharmaceutical Collection: A comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics (2011, background): “For example, using such an approach the antibiotic ceftriaxone was determined to represent a possible treatment for amyotrophic lateral sclerosis (17), and the antihistamine astemizole was identified as a potential antimalarial drug (18).”
• Astrocyte reactivity and reactive astrogliosis: costs and benefits. (2014, background): “Another screen of FDA-approved drugs, this time for their ability to stimulate the expression of glutamate transporter GLT1 (EAAT2) by astrocytes, helped to identify ceftriaxone, a representative of beta-lactam antibiotics, as a compound which was successfully applied to slow down progression of amy”
• Chronic Glutamate Toxicity in Neurodegenerative Diseases—What is the Evidence? (2015, background): “Cef is perhaps the best studied of these compounds and has been tested in models of AD (Zumkehr et al., 2015), HD (Miller et al., 2008), and ALS (Rothstein et al., 2005) with positive results.”
• Astrocytes, from brain glue to communication elements: the revolution continues (2005, background): “143 ), a defect also observed in patients with sporadic ALS that is probably involved in the pathogenesis of the diseas”
• Astrocytes: biology and pathology (2009, background): “A high-throughput screen of small molecules has identified that certain b-lactam antibiotics can stimulate the expression of glutamate transporters by astrocyte and thereby enhance glutamate uptake sufficiently to reduce excitotoxicity, and provide neuroprotection in animal models of stroke and ALS ”